Literature DB >> 21308547

In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Susanne Perkhofer1, Cornelia Mrazek, Lukas Hartl, Cornelia Lass-Flörl.   

Abstract

An increasing number of patients are undergoing transplantation procedures or receiving aggressive immunosuppression and chemotherapy. The growing population of immunocompromised hosts has led to a rise in the prevalence of invasive fungal infections due to yeasts and molds. The introduction of new antifungal agents and recent reports of resistance emerging during treatment of fungal infections have highlighted the need for in vitro susceptibility testing. Various testing procedures have been proposed, including macrodilution and microdilution, agar diffusion, disk diffusion, and Etest (AB Biodisk, Solna, Sweden). Establishing clinical correlation with antifungal susceptibility testing, however, is a huge challenge because susceptibility techniques do not take into account the dynamic and complex biology of fungi exposed to an antifungal in vivo. This paper reviews the available methods for antifungal susceptibility testing of yeasts and filamentous fungi and the data regarding the clinical implications of in vitro testing.

Entities:  

Year:  2010        PMID: 21308547     DOI: 10.1007/s11908-010-0134-z

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  46 in total

1.  Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi.

Authors:  A Aberkane; M Cuenca-Estrella; A Gomez-Lopez; E Petrikkou; E Mellado; A Monzón; J L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

2.  Multidrug resistance in Aspergillus fumigatus.

Authors:  Adilia Warris; Corry M Weemaes; Paul E Verweij
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

3.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

4.  Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Authors:  M Cuenca-Estrella; M C Arendrup; E Chryssanthou; E Dannaoui; C Lass-Florl; P Sandven; A Velegraki; J L Rodriguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2007-08-13       Impact factor: 8.067

5.  EUCAST technical note on fluconazole.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2007-12-05       Impact factor: 8.067

6.  MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole.

Authors:  Carine Marinach; Alexandre Alanio; Martine Palous; Stéphanie Kwasek; Arnaud Fekkar; Jean-Yves Brossas; Sophie Brun; Georges Snounou; Christophe Hennequin; Dominique Sanglard; Annick Datry; Jean-Louis Golmard; Dominique Mazier
Journal:  Proteomics       Date:  2009-10       Impact factor: 3.984

7.  Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp.

Authors:  E Chryssanthou; M Cuenca-Estrella
Journal:  Clin Microbiol Infect       Date:  2006-09       Impact factor: 8.067

8.  Relationship between susceptibility of Candida spp. isolates to amphotericin B and death or survival of patients with candidemia episodes.

Authors:  Sydney Hartz Alves; Everton Boff; Patricia Pozzatti; Liliane A Scheid; Erico de Loreto; Loiva T Ottoneli Oliveira; Valério Aquino; Luiz Carlos Severo; Janio Morais Santurio
Journal:  Mycopathologia       Date:  2008-09-26       Impact factor: 2.574

9.  Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.

Authors:  Elizabeth Johnson; Ana Espinel-Ingroff; Adrien Szekely; Hans Hockey; Peter Troke
Journal:  Int J Antimicrob Agents       Date:  2008-09-13       Impact factor: 5.283

10.  In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods.

Authors:  Josep M Torres-Rodríguez; Eidi Alvarado-Ramírez
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

View more
  6 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Rapid identification of Aspergillus terreus from bronchoalveolar lavage fluid by PCR and electrospray ionization with mass spectrometry.

Authors:  Dhruvangkumar A Modi; John J Farrell; Rangarajan Sampath; Nisha S Bhatia; Christian Massire; Ray Ranken; Robert A Bonomo
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

3.  Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.

Authors:  Michael A Pfaller; Shawn A Messer; Leah N Woosley; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

4.  New Antifungal Susceptibility Test Based on Chitin Detection by Image Cytometry.

Authors:  Yan Wang; Arisandy N Andriampamonjy; Sebastien Bailly; Cécile Garnaud; Danièle Maubon; Muriel Cornet; Delphine Aldebert
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

5.  Evaluation of a novel oxiconazole nitrate formulation: The thermosensitive gel.

Authors:  Alper Arslan; Cansel Kose Ozkan; Ali Korhan Sig; Eyup Dogan; Ozgur Esim; Serdar Cetinkaya; Filiz Atalay; Cetin Tas; Ayhan Savaser; Yalcin Ozkan
Journal:  Saudi Pharm J       Date:  2018-02-19       Impact factor: 4.330

6.  Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical.

Authors:  Arnaldo Lopes Colombo; Thaís Guimarães; Luis Fernando Aranha Camargo; Rosana Richtmann; Flavio de Queiroz-Telles; Mauro José Costa Salles; Clóvis Arns da Cunha; Maria Aparecida Shikanai Yasuda; Maria Luiza Moretti; Marcio Nucci
Journal:  Braz J Infect Dis       Date:  2013-05-18       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.